The Efficacy and Safety of Bionic Tiger Bone Powder for the Treatment of Knee Osteoarthritis in Early Stage: A Randomized, Double-Blind, Placebo-Controlled, Multicenter Clinical Trial.

Objective • This study evaluated the efficacy and safety of bionic tiger bone powder (Jintiange) in comparison to placebo in treating knee osteoarthritis osteoporosis. Methods • A total of 248 patients were randomly allocated to a Jintiange group or a placebo group, undergoing 48 weeks of double-blind treatment. The Lequesne index, clinical symptoms, safety index (adverse events), and Patient’s Global Impression of Change score were recorded at pre-determined time intervals. All P values ≤ .05 were deemed statistically significant. Results • Both groups showed a decreasing trend in the Lequesne index, with the Jintiange group’s reduction significantly larger from the 12th week (P≤.01). Similarly, the effective rate of Lequesne score in the Jintiange group was significantly higher (P<.001). After 48 weeks, clinical symptom score differences between the Jintiange group (2.46 ± 1.74) and the placebo group (1.51 ± 1.73) were statistically significant (P<.05), as were differences in the Patient’s Global Impression of Change score (P < .05). Adverse drug reactions were minimal with no significant difference between the groups (P>.05). Conclusion • Jintiange demonstrated superior efficacy over placebo in treating knee osteoporosis, with comparable safety profiles. Findings warrant further comprehensive real-world studies. [ABSTRACT FROM AUTHOR]